Epstein-Barr virus-induced gene 2 (EBI2, also known as GPR183) is a G-protein-coupled receptor that is required for humoral immune responses; polymorphisms in the receptor have been associated with inflammatory autoimmune diseases [1] [2] [3] . The natural ligand for EBI2 has been unknown. Here we describe the identification of 7a,25-dihydroxycholesterol (also called 7a,25-OHC or 5-cholesten-3b,7a,25-triol) as a potent and selective agonist of EBI2. Functional activation of human EBI2 by 7a,25-OHC and closely related oxysterols was verified by monitoring second messenger readouts and saturable, high-affinity radioligand binding. Furthermore, we find that 7a,25-OHC and closely related oxysterols act as chemoattractants for immune cells expressing EBI2 by directing cell migration in vitro and in vivo. A critical enzyme required for the generation of 7a,25-OHC is cholesterol 25-hydroxylase (CH25H) 4 . Similar to EBI2 receptor knockout mice, mice deficient in CH25H fail to position activated B cells within the spleen to the outer follicle and mount a reduced plasma cell response after an immune challenge. This demonstrates that CH25H generates EBI2 biological activity in vivo and indicates that the EBI2-oxysterol signalling pathway has an important role in the adaptive immune response.
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Screening of a liver extract from a peritonitis sheep sepsis model in a functional assay format detecting release of intracellular calcium identified a bioactivity specific for human EBI2 (Fig. 1a) . After characterization of biophysical properties (for example, protease resistance), 2 kg of sheep liver were extracted and fractionated over six steps of liquid chromatography ( Supplementary Fig. 1 ), which yielded pure fractions potently activating the human EBI2 receptor.
Mass spectrometry (MS) analysis of the active fractions using nano electrospray ionization-Fourier transform MS (NanoESI-FTMS) showed four peaks with significant intensities in both step 5 (Supplementary Fig. 1e , Active 1) and step 6 ( Supplementary Fig. 1f , Active 2), which were negligible in control samples ( Supplementary  Fig. 2 commercially available. Among the tested compounds two related oxysterols, cholest-5-ene-3b,7b,25-triol (7b,25-OHC) and cholest-5-ene-3b,7b-diol (7b-OHC), induced specific activation of the human EBI2 receptor with half-maximum effective concentration (EC 50 ) values close to 50 nM and 15 mM, respectively, whereas the 7-methoxy derivate of 7b-OHC did not activate EBI2, indicating some structure activity relationship ( Supplementary Fig. 3 ).
In contrast to 7a,25-OHC, for which a clear metabolic pathway has been described 4 , the generation of 7b,25-OHC in vivo is still unclear 5 .
Switzerland. *These authors contributed equally to this work. This information prompted us to synthesize 7a,25-OHC (Fig. 1b) , which proved to be more potent than 7b,25-OHC (Fig. 1c) . While the purification from septic sheep liver was in progress, we also initiated a parallel approach using pig liver tissue (starting material 10 kg). After five liquid chromatography separation steps, ions with masses m/z 365.3202, 383.3311, 401.3411 and 441.333 were observed in positive ion mode, rationalized as
H-NMR analysis of the active fraction, a scale-up of the purification using 35 kg pig liver tissue yielded about 100 mg of substantially pure EBI2 ligand. 1 H-NMR analysis comparing EBI2 ligand purified from pig liver with synthetic 7a,25-OHC confirmed the molecular identity of the two compounds ( Supplementary Fig. 4 ), indicating that 7a,25-OHC is the naturally occurring receptor ligand.
After identification of 7a,25-OHC as an EBI2 agonist, we conducted a pharmacological characterization of 7a,25-OHC and closely related oxysterols using two functional second messenger readouts (release of intracellular calcium (Fig. 1c) and binding of GTP-cS; see Table 1 ). Other than the hydroxylation at the 3 position, hydroxylations at the 7 and at the 25 positions were necessary for potent activation of EBI2. At the 7 position the axial a position was much preferred over the equatorial b position. Hydroxylation of the side chain at the 25 position was preferred but hydroxylation at the 27 position also led to a strong activation. Parental cells lacking the EBI2 receptor did not respond to the tested oxysterols (data for 7a,25-OHC are shown in Fig. 1c ; data for the other oxysterols are omitted for clarity). To characterize binding of oxysterols to the EBI2 receptor we developed a suitable radioligand. Reduction of 7-keto,25-OHC using tritiated L-selectride led to the formation of [ . In addition, oxysterol-dependent activation of the nuclear hormone receptor LXR has recently been implicated in the acquired immune response 7 . To assess possible interaction of the most potent EBI2 ligands with other receptors we tested 7a,25-OHC and 7a,27-OHC in a panel of reporter gene assays against eight different nuclear hormone receptors including LXR and thirty-one different G-protein-coupled receptors. In none of these assays did we see a significant interaction between 7a,25-OHC or 7a,27-OHC and the tested partner (see Supplementary Information) .
B cells in different stages of maturation show a distinct profile of EBI2 expression. It is abundant in naive B cells and further upregulated early after their activation by antigen, whereas B cells from germinal centres sharply downregulate EBI2 expression. Once affinity maturation has been completed and the B cells differentiate into plasma or memory cells, EBI2 is again expressed. This expression pattern combined with the recent finding that EBI2 is a key regulator positioning B cells in lymphoid organs 1,2 prompted us to investigate oxysterols as chemoattractants in a transwell assay system. For this experiment we used either an Epstein-Barr-virus (EBV)-infected human B cell line or a Burkitt's lymphoma pre-B-cell line called RS11846 (refs 8, 9) . Both cell lines displayed high endogenous EBI2 expression ( Supplementary  Fig. 6 ). We found that 7a,25-OHC can potently attract EBV-infected B cells or RS11846 cells (Fig. 2a, b) . Similar to classical chemokines, we found a bell-shaped activity curve in the transwell assay that indicates reduced attraction at high compound concentrations. Oxysterols closely related to 7a,25-OHC can also attract RS11846 cells albeit with lower potency. The rank order of different oxysterols in the migration assay was identical to the rank order in the functional and binding assays. The attraction of EBI2-expressing RS11846 cells could be blocked by pertussis toxin, a reagent that blocks signalling of Ga i -coupled receptors (Fig. 2c) . Oxysterol-mediated chemoattraction is not limited to B-lineage cells but can also be observed with other immune cells (for example, dendritic cells) expressing EBI2. Messenger RNA expression Supplementary Fig. 7 ). Testing of bone-marrow-derived dendritic cells 11 from wild-type and Ebi2
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mice in the transwell migration assay showed that only wild-type cells migrate towards 7a,25-OHC (Fig. 2d) . Identification of the chemoattractant properties of oxysterols on B cells and the previous findings regarding EBI2-deficient B cells 1, 2 suggested that ablation of enzymes necessary for ligand production will have an impact on the B-cell trafficking after an immune challenge. The defined biosynthetic pathway of the more potent 7a,25-OHC requires the activity of cholesterol 25-hydroxylase (CH25H) 4 and oxysterol 7a-hydroxylase (CYP7B1) 4 . Both of these enzymes are abundantly expressed in spleen and lymph nodes (Fig. 3a) . To determine whether CH25H deficiency affected EBI2 ligand production, tissue extracts were prepared from wild-type and Ch25h 2/2 (ref. 12) spleen and lymph nodes and tested for their ability to attract an EBI2-expressing cell line in a bioassay that has subnanomolar sensitivity for 7a,25-OHC (Supplementary Fig. 8c ). Whereas wild-type tissue extracts showed readily identifiable activity, extracts from Ch25h 2/2 mice lacked activity in this bioassay (Fig. 3b) . In addition, spleen extracts from mice reconstituted with bone marrow transduced with a CH25H-expressing retroviral vector showed a greatly increased tendency to attract EBI2-expressing cells (Fig. 3c) . Consistent with evidence that CH25H expression is increased by lipopolysaccharide (LPS) exposure 13 , the bioactivity in spleen extracts from 6-and 16-h treated mice was increased several fold ( Supplementary Fig. 8a, b) . Using mass spectrometry we assessed the production of 7a,25-OHC in the spleen of unchallenged and LPSchallenged mice (Supplementary Fig. 8d) . A peak corresponding to 7a,25-OHC was clearly detectable in tissue prepared from LPSchallenged wild-type mice, but was close to the detection limit or undetectable in unchallenged wild-type or Ch25h 2/2 mice. The origin of the weak signal detected in some samples derived from Ch25h 2/2 mice is not yet clear and could be due to the production of low amounts of 7a,25-OHC via enzymes other than CH25H (refs 14-16) . These results indicate that in an LPS immune challenge, 7a,25-OHC is generated in the spleen in a CH25H-dependent manner.
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at day 21 and were immunized with HEL-OVA at day 0 and analysed at day 2 for their immune response. Visualization of activated B cells (IgM a ) in the spleen relative to the position of marginal metallophilic macrophages (Moma1) (Fig. 3d) or endogenous follicular B cells ( Supplementary Fig. 9 ) showed that at day 2 after immune challenge in wild-type recipients, many of the activated B cells had moved to the back of the follicle and interfollicular regions whereas in Ch25h 2/2 mice activated B cells largely failed to move to these regions and instead remained near the follicle-T-zone interface or moved into the follicle (Fig. 3d, e and Supplementary Fig. 9 ). The defective distribution of activated B cells in CH25H-deficient mice was similar to that reported for day 2 activated EBI2-deficient B cells 1 . Migration assays with spleen cells prepared at the same time point showed that the day 2 activated wild-type MD4 B cells responded more vigorously than naive endogenous B cells to 7a,25-OHC (Fig. 3f) . Both the baseline naive B-cell response and the increased response of activated B cells required EBI2 expression (Supplementary Fig. 10 ) and MD4 B cells that had not been exposed to antigen did not show an augmented response ( Supplementary Fig. 10 ). EBI2 bioactivity was similar in spleen extracts from day 2 immunized and unimmunized mice ( Supplementary  Fig. 10 ). Ch25h and Cyp7b1 transcript abundance was low in B and T lymphocytes but enriched in stromal cells (Fig. 3a) , indicating that the enzymes are expressed in adhesive myeloid or mesenchymal cells, consistent with studies on other tissues 13, 17, 18 . Although it has not been possible to determine enzyme distribution in tissue sections with existing antibody reagents and no tools are available to visualize ligand distribution, based on the EBI2-dependent homing properties of activated B cells we speculate that ligand abundance is higher in outer and interfollicular regions compared to the follicle centre. Finally, we tested whether ligand deficiency led to a defect in the plasma cell response. Five days after immunization with a T-dependent antigen (sheep red blood cells), the CH25H-deficient mice showed a ,3-fold defect in the magnitude of their IgG1 plasma cell response (Fig. 3g) , an impairment very similar to that observed in EBI2-deficient mice 1, 2 . We have identified the natural ligand for EBI2 and delineated its physiological function as a chemoattractant in the immune system 1, 2 . Our results provide an unanticipated link between recent results showing a crucial role for EBI2 in promoting B-cell localization within lymphoid organs, of EBI2 connecting through IRF7 to regulate a macrophage-associated autoimmune disease 3 and studies highlighting how oxysterols shape the innate and adaptive immune responses 12, 13, 19 . Together with these published reports, our results establish a new physiological dimension for oxysterols as bioactive signalling molecules.
Note added in proof: An independent study has obtained similar results identifying oxysterols as EBI2 ligands directing B-cell migration 20 .
METHODS SUMMARY
Compounds. 7a,25-OHC (CAS no. 64907-22-8) and 7b,25-OHC (CAS no. 64907-21-7) were synthesized either in a one-step reaction from the 7-keto precursor (see Supplementary Information), or in a four-step synthesis according to published procedures 21 . 7a,27-OHC (CAS no. 144300-24-3) and 7b,27-OHC (CAS no. 240129-43-5) were purchased from Avanti Polar Lipids Inc. 7a-OHC (CAS no. 566-26-7) was batch synthesized at Novartis. 7b-OHC (CAS no. 566-27-8), 25-OHC (CAS no. 2140-46-7) and cholesterol (CAS no. 57-88-5) were purchased from Sigma-Aldrich. EBI2 recombinant cell line. The human EBI2 gene was cloned using RT-PCR from HL-60 cDNA and corresponded to the GenBank accession number NP_004942. Human EBI2 was inserted into the pEFIN3 vector at the EcoR1 and Xbal sites in the multiple cloning site. Plasmids expressing human EBI2 were stably transfected in CHO-K1 expressing the apo-aequorin and Gqi5 to yield CHO/Aeq/Gqi5/hEBI2. Tissue extract preparation. Extraction of sheep tissue was done by methanol/ water/acetic acid (90:9:1) whereas pig tissue was extracted using hexane/isopropanol (1:1). Methods for separation of crude extracts as well as details on the pharmacological characterization and spectroscopic methods used can be found in Supplementary Information.
